The role of dopamine in huntington's disease

Progress in Brain Research

Volumn 211, Issue , 2014, Pages 235-254

  Cepeda, Carlos ^a   Murphy, Kerry P S ^b   Parent, Martin ^c   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OPEN UNIVERSITY   (United Kingdom)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Dopamine; Glutamate; Huntington's disease; Medium sized spiny neurons; Neurotransmission; Receptors

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL MODEL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CADAVER; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; EXCITOTOXICITY; GENETIC MODEL; HUMAN; HUNTINGTON CHOREA; INNERVATION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; STRIATE CORTEX; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DOPAMINE; HUMANS; HUNTINGTON DISEASE; SYNAPTIC TRANSMISSION;

EID: 84904644037     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63425-2.00010-6     Document Type: Chapter

References (135)

1. Afifi A.K., Bahuth N.B., Kaelber W.W., Mikhael E., Nassar S. The cortico-nigral fibre tract. An experimental Fink-Heimer study in cats. J. Anat. 1974, 118:469-476.
2. André V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., Yang X.W., Levine M.S. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J. Neurosci. 2011, 31:1170-1182.
3. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 2002, 68:716-729.
4. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 1997, 283:226-234.
5. Backman L., Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand. J. Psychol. 2001, 42:287-296.
6. Baker S.A., Baker K.A., Hagg T. Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur. J. Neurosci. 2004, 20:575-579.
7. Bedard C., Wallman M.J., Pourcher E., Parent A., Parent M. Intense dopamine innervation of the subventricular zone in Huntington's disease. Neuroreport 2010, 21:1074-1079.
8. Bedard C., Wallman M.J., Pourcher E., Gould P.V., Parent A., Parent M. Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism Relat. Disord. 2011, 17:593-598.
9. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
10. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6809-6814.
11. Bird E.D. Chemical pathology of Huntington's disease. Annu. Rev. Pharmacol. Toxicol. 1980, 20:533-551.
12. Bird E.D., Iversen L.L. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 1974, 97:457-472.
13. Bird E.D., Spokes E.G., Iversen L.L. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr. Scand. Suppl. 1980, 280:63-73.
14. Bohnen N.I., Koeppe R.A., Meyer P., Ficaro E., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000, 54:1753-1759.
15. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 2006, 12:2701-2720.
16. Bozzi Y., Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci. 2006, 29:167-174.
17. Brusa L., Orlacchio A., Moschella V., Iani C., Bernardi G., Mercuri N.B. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov. Disord. 2009, 24:126-129.
18. Bylsma F.W., Peyser C.E., Folstein S.E., Folstein M.F., Ross C., Brandt J. EEG power spectra in Huntington's disease: clinical and neuropsychological correlates. Neuropsychologia 1994, 32:137-150.
19. Callahan J.W., Abercrombie E.D. In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington's disease. Front. Syst. Neurosci. 2011, 5:61.
20. Caraceni T.A., Girotti F., Giovannini P., Pederzoli M., Parati E.A. Effects of DA agonist in Huntington disease hyperkinesia. Ital. J. Neurol. Sci. 1980, 1:155-161.
21. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9576-9580.
22. Cepeda C., Colwell C.S., Itri J.N., Chandler S.H., Levine M.S. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J. Neurophysiol. 1998, 79:82-94.
23. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23:961-969.
24. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
25. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6480-6485.
26. Charvin D., Vanhoutte P., Pages C., Borrelli E., Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12218-12223.
27. Charvin D., Roze E., Perrin V., Deyts C., Betuing S., Pages C., Regulier E., Luthi-Carter R., Brouillet E., Deglon N., Caboche J. Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol. Dis. 2008, 29:22-29.
28. Chen J.J., Ondo W.G., Dashtipour K., Swope D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin. Ther. 2012, 34:1487-1504.
29. Cossette M., Parent A., Levesque D. Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur. J. Neurosci. 2004, 20:2089-2095.
30. Cossette M., Levesque D., Parent A. Neurochemical characterization of dopaminergic neurons in human striatum. Parkinsonism Relat. Disord. 2005, 11:277-286.
31. Cossette M., Lecomte F., Parent A. Morphology and distribution of dopaminergic neurons intrinsic to the human striatum. J. Chem. Neuroanat. 2005, 29:1-11.
32. Cummings D.M., Milnerwood A.J., Dallerac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:2856-2868.
33. Cummings D.M., Milnerwood A.J., Dallérac G.M., Vatsavayai S.C., Hirst M.C., Murphy K.P.S.J. Abnormal cortical synaptic plasticity in mice transgenic for exon 1 of the human Huntington's disease mutation. Brain Res. Bull. 2007, 72:103-107.
34. Curtis M.A., Eriksson P.S., Faull R.L. Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin. Exp. Pharmacol. Physiol. 2007, 34:528-532.
35. Dallerac G.M., Vatsavayai S.C., Cummings D.M., Milnerwood A.J., Peddie C.J., Evans K.A., Walters S.W., Rezaie P., Hirst M.C., Murphy K.P. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener. Dis. 2011, 8:230-239.
36. Davis S., Brotchie J., Davies I. Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia. Exp. Neurol. 2002, 176:229-236.
37. de Yebenes J.G., Landwehrmeyer B., Squitieri F., Reilmann R., Rosser A., Barker R.A., Saft C., Magnet M.K., Sword A., Rembratt A., Tedroff J. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011, 10:1049-1057.
38. Ferrante R.J., Kowall N.W. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Res. 1987, 416:141-146.
39. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., Richardson E.P. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1987, 46:12-27.
40. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C.R., Jokel E.S., Fienberg A.A., Greengard P., Levine M.S. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 2002, 88:3010-3020.
41. Foroud T., Siemers E., Kleindorfer D., Bill D.J., Hodes M.E., Norton J.A., Conneally P.M., Christian J.C. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann. Neurol. 1995, 37:657-664.
42. Frattola L., Albiazzati M.G., Spano P.F., Trabucchi M. Treatment of Huntington's chorea with bromocriptine. Acta Neurol. Scand. 1977, 56:37-45.
43. Freeman W., Morton A.J. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 2004, 63:45-55.
44. Fuster J.M. Prefrontal neurons in networks of executive memory. Brain Res. Bull. 2000, 52:331-336.
45. Garrett M.C., Soares-da-Silva P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J. Neurochem. 1992, 58:101-106.
46. Gibb W.R. Neuropathology of the substantia nigra. Eur. Neurol. 1991, 31(Suppl. 1):48-59.
47. Gibson H.E., Reim K., Brose N., Morton A.J., Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci. 2005, 22:1701-1712.
48. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120(Pt 3):503-514.
49. Goldman-Rakic P.S. Cellular basis of working memory. Neuron 1995, 14:477-485.
50. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227:770-773.
51. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
52. Gurden H., Takita M., Jay T.M. Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J. Neurosci. 2000, 20:RC106.
53. Harper P.S. New genes for old diseases: the molecular basis of myotonic dystrophy and Huntington's disease. The Lumleian Lecture 1995. J. R. Coll. Physicians Lond. 1996, 30:221-231.
54. Haskins B.A., Harrison M.B. Huntington's disease. Curr. Treat. Options Neurol. 2000, 2:243-262.
55. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1995, 54:105-120.
56. Hedreen J.C., Peyser C.E., Folstein S.E., Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 1991, 133:257-261.
57. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
58. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
59. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., Hirsch E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 2004, 7:726-735.
60. Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
61. Huot P., Parent A. Dopaminergic neurons intrinsic to the striatum. J. Neurochem. 2007, 101:1441-1447.
62. Huot P., Levesque M., Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007, 130:222-232.
63. Ibanez-Sandoval O., Tecuapetla F., Unal B., Shah F., Koos T., Tepper J.M. Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J. Neurosci. 2010, 30:6999-7016.
64. Ilyin V.I., Whittemore E.R., Guastella J., Weber E., Woodward R.M. Subtype-selective inhibition of N-methyl-d-aspartate receptors by haloperidol. Mol. Pharmacol. 1996, 50:1541-1550.
65. Jahanshahi A., Vlamings R., Kaya A.H., Lim L.W., Janssen M.L., Tan S., Visser-Vandewalle V., Steinbusch H.W., Temel Y. Hyperdopaminergic status in experimental Huntington disease. J. Neuropathol. Exp. Neurol. 2010, 69:910-917.
66. Jahanshahi A., Vlamings R., van Roon-Mom W.M., Faull R.L., Waldvogel H.J., Janssen M.L., Yakkioui Y., Zeef D.H., Kocabicak E., Steinbusch H.W., Temel Y. Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease. Neuroscience 2013, 238:71-81.
67. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 2000, 23:239-245.
68. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
69. Joshi P.R., Wu N.P., Andre V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
70. Kalivas P.W., Duffy P., Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 1989, 251:378-387.
71. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Kanki R., Yamashita H., Akaike A. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci. Res. 2002, 70:274-282.
72. Kish S.J., Shannak K., Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann. Neurol. 1987, 22:386-389.
73. Klawans H.C., Paulson G.W., Barbeau A. Predictive test for Huntington's chorea. Lancet 1970, 2:1185-1186.
74. Kornhuber J., Kim J.S., Kornhuber M.E., Kornhuber H.H. The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 1984, 322:124-126.
75. Kowall N.W., Ferrante R.J., Martin J.B. Patterns of cell loss in Huntington's disease. Trends Neurosci. 1987, 10:24-29.
76. Kung V.W., Hassam R., Morton A.J., Jones S. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 2007, 146:1571-1580.
77. Lao C.L., Lu C.S., Chen J.C. Dopamine D3 receptor activation promotes neural stem/progenitor cell proliferation through AKT and ERK1/2 pathways and expands type-B and -C cells in adult subventricular zone. Glia 2013, 61:475-489.
78. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain J. Neurol. 1998, 121(Pt 7):1329-1341.
79. Lobo M.K., Yeh C., Yang X.W. Pivotal role of early B-cell factor 1 in development of striatonigral medium spiny neurons in the matrix compartment. J. Neurosci. Res. 2008, 86:2134-2146.
80. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
81. Massouh M., Wallman M.J., Pourcher E., Parent A. The fate of the large striatal interneurons expressing calretinin in Huntington's disease. Neurosci. Res. 2008, 62:216-224.
82. Maurice N., Deniau J.M., Glowinski J., Thierry A.M. Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the cortico-nigral circuits. J. Neurosci. 1999, 19:4674-4681.
83. McGeer P.L., McGeer E.G. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea. J. Neurochem. 1976, 26:65-76.
84. McLaughlin B.A., Nelson D., Erecinska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 1998, 70:2406-2415.
85. Meltzer L.T., Christoffersen C.L., Serpa K.A. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci. Biobehav. Rev. 1997, 21:511-518.
86. Mestre T.A., Ferreira J.J. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat. Disord. 2012, 18:316-320.
87. Milner A.J., Cummings D.M., Spencer J.P., Murphy K.P. Bi-directional plasticity and age-dependent long-term depression at mouse CA3-CA1 hippocampal synapses. Neurosci. Lett. 2004, 367:1-5.
88. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1690-1703.
89. Mochel F., Durant B., Durr A., Schiffmann R. Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS One 2011, 6:e18336.
90. Murase S., Grenhoff J., Chouvet G., Gonon F.G., Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett. 1993, 157:53-56.
91. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 2000, 20:5115-5123.
92. Nieoullon A., Cheramy A., Glowinski J. Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res. 1978, 145:69-83.
93. Orth M., Schippling S., Schneider S.A., Bhatia K.P., Talelli P., Tabrizi S.J., Rothwell J.C. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:267-270.
94. Ortiz A.N., Kurth B.J., Osterhaus G.L., Johnson M.A. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 2010, 112:755-761.
95. Ortiz A.N., Osterhaus G.L., Lauderdale K., Mahoney L., Fowler S.C., von Horsten S., Riess O., Johnson M.A. Motor function and dopamine release measurements in transgenic Huntington's disease model rats. Brain Res. 2012, 1450:148-156.
96. Oyanagi K., Takeda S., Takahashi H., Ohama E., Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 1989, 26:13-19.
97. Paoletti P., Vila I., Rife M., Lizcano J.M., Alberch J., Gines S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 2008, 28:10090-10101.
98. Parent M., Bedard C., Pourcher E. Dopaminergic innervation of the human subventricular zone: a comparison between Huntington's chorea and Parkinson's disease. Am. J. Neurodegener. Dis. 2013, 2:221-227.
99. Petersen A.A., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., Sulzer D. Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res. Bull. 2001, 56:331-335.
100. Petersen A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
101. Phillips W., Shannon K.M., Barker R.A. The current clinical management of Huntington's disease. Mov. Disord. 2008, 23:1491-1504.
102. Pifl C., Pichler L., Kobinger W., Hornykiewicz O. The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat. Eur. J. Pharmacol. 1988, 153:33-44.
103. Porritt M.J., Batchelor P.E., Hughes A.J., Kalnins R., Donnan G.A., Howells D.W. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000, 356:44-45.
104. Pouladi M.A., Stanek L.M., Xie Y., Franciosi S., Southwell A.L., Deng Y., Butland S., Zhang W., Cheng S.H., Shihabuddin L.S., Hayden M.R. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 2012, 21:2219-2232.
105. Prensa L., Cossette M., Parent A. Dopaminergic innervation of human basal ganglia. J. Chem. Neuroanat. 2000, 20:207-213.
106. Reiner A., Shelby E., Wang H., Demarch Z., Deng Y., Guley N.H., Hogg V., Roxburgh R., Tippett L.J., Waldvogel H.J., Faull R.L. Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia. Mov. Disord. 2013, 28:1691-1699.
107. Richardson E.P. Third Dorothy S. Russell memorial lecture. Huntington's disease: some recent neuropathological studies. Neuropathol. Appl. Neurobiol. 1990, 16:451-460.
108. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 1991, 132:121-126.
109. Sandstrom M.I., Steffes-Loydahl S., Jayaprakash N., Wolfram-Aduan A., Dunbar G.L. Early dysfunction of neural transmission and cognitive processing in Huntington's disease. Huntington's Disease - Core Concepts and Current Advances 2010, 201-232. InTech, New York, NY. N. Tunali (Ed.).
110. Sapp E., Kegel K.B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P.G., Vonsattel J.P., DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
111. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 1998, 44:110-119.
112. Sesack S.R., Carr D.B. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol. Behav. 2002, 77:513-517.
113. Shen S., Pu J., Lang B., McCaig C.D. A zinc finger protein Zfp521 directs neural differentiation and beyond. Stem Cell Res. Ther. 2011, 2:20.
114. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
115. Spargo E., Everall I.P., Lantos P.L. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry 1993, 56:487-491.
116. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980, 103:179-210.
117. Suzuki M., Desmond T.J., Albin R.L., Frey K.A. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 2001, 41:329-336.
118. Tang T.S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
119. Tedroff J., Ekesbo A., Sonesson C., Waters N., Carlsson A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 1999, 53:1605-1606.
120. Thiruvady D.R., Georgiou-Karistianis N., Egan G.F., Ray S., Sritharan A., Farrow M., Churchyard A., Chua P., Bradshaw J.L., Brawn T.L., Cunnington R. Functional connectivity of the prefrontal cortex in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:127-133.
121. Usdin M.T., Shelbourne P.F., Myers R.M., Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 1999, 8:839-846.
122. van der Hiele K., Jurgens C.K., Vein A.A., Reijntjes R.H., Witjes-Ane M.N., Roos R.A., van Dijk G., Middelkoop H.A. Memory activation reveals abnormal EEG in preclinical Huntington's disease. Mov. Disord. 2007, 22:690-695.
123. Van Kampen J.M., Hagg T., Robertson H.A. Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur. J. Neurosci. 2004, 19:2377-2387.
124. van Oostrom J.C., Dekker M., Willemsen A.T., de Jong B.M., Roos R.A., Leenders K.L. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur. J. Neurol. 2009, 16:226-231.
125. Venuto C.S., McGarry A., Ma Q., Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov. Disord. 2012, 27:31-41.
126. von Horsten S., et al. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
127. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
128. Vonsattel J.P., Keller C., Del Pilar Amaya M. Neuropathology of Huntington's disease. Handb. Clin. Neurol. 2008, 89:599-618.
129. Walker A.G., Miller B.R., Fritsch J.N., Barton S.J., Rebec G.V. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. J. Neurosci. 2008, 28:8973-8982.
130. Wang J., O'Donnell P. D(1) dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb. Cortex 2001, 11:452-462.
131. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
132. Williams G.V., Castner S.A. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006, 139:263-276.
133. Wu J., Tang T., Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci. Lett. 2006, 407:219-223.
134. Yohrling G.J.t., Jiang G.C., DeJohn M.M., Miller D.W., Young A.B., Vrana K.E., Cha J.H. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res. Mol. Brain Res. 2003, 119:28-36.
135. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.